| Similar Articles |
|---|
 |
The Motley Fool
September 27, 2007
Ryan Fuhrmann |
Chattem Chugs Along Shares of Chattem hit a new high today on solid results, and management ups its guidance, but what does that mean going forward? Investors should take note.   |
The Motley Fool
July 11, 2007
Brian Orelli |
Icy Hot Results From Chattem The manufacturer of over-the-counter health-care products sees a huge increase in sales, but can it last? Investors, take note. |
The Motley Fool
October 11, 2006
Brian Lawler |
Monopoly Woes Help Chattem Grow Acquisitions boost the health-care brand owner's shares to new highs. |
The Motley Fool
March 19, 2007
Rich Duprey |
Foolish Forecast: Chatting Up Chattem The consumer products company will report first-quarter 2007 financial results shortly. Investors, here is what you can expect to see. |
The Motley Fool
July 12, 2007
Jeremy MacNealy |
Fool on Call: Chattem Looks Toward a Record '08 Timely acquisitions and cost savings add up to a big year for this consumer-goods producer. Prospective investors should at least take a closer look. |
The Motley Fool
September 20, 2005
Jeremy MacNealy |
Chattem's Icy Hot Stock The stock of this manufacturer of over-the-counter health-care products is on an exceptional run. Shareholders may be wondering whether this is a good time to take some money off the table. |
The Motley Fool
June 20, 2005
Matt Thurmond |
Chattem's High-Dollar Brands Health-care product maker generates big bucks from the body's annoying little problems. |
The Motley Fool
March 26, 2007
Rich Duprey |
Breaking Chattem's Bond The consumer-products company should continue to give shareholders that soothing feeling. |
The Motley Fool
April 17, 2006
Stephen D. Simpson |
Chattin' Up Chattem Great brands owned by a boring and unknown company. Might there be value afoot for investors? |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
July 10, 2006
Stephen D. Simpson |
Chattem Holds Its Ground Management seems to have more faith in this consumer-goods company's business than Wall Street does. It is likely not a stock for the faint of heart. |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
February 13, 2007
Rich Duprey |
Chattem Has Relief on the Way The consumer products company has a portfolio of new products to drive revenues and profits. Investors, take note. |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
The Motley Fool
May 17, 2006
Stephen D. Simpson |
Better Days in Sight for Church & Dwight The transition from acquirer to operator isn't easy, but the company seems to be managing. The market seems to know that, as these shares aren't priced for value investors, even if you give them some pretty healthy benefits of the doubt. |
The Motley Fool
September 17, 2004
David Meier |
Gettin' Funky With Chattem Is Chattem good enough for your portfolio? |
The Motley Fool
December 22, 2009
Brian Orelli |
This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis. |
The Motley Fool
May 10, 2006
Stephen D. Simpson |
A Broad Spectrum of Disappointment Will management at this company formerly known as Rayovac find a way to meet expectations? Investors, take note. |
The Motley Fool
March 25, 2011
Brian Orelli |
Teva:P&G :: Peanut Butter:Chocolate The generic-drug maker and consumer-products company are forming a joint venture to sell over-the-counter medication, with both companies bringing their strengths to the table. |
The Motley Fool
September 29, 2011
Brian Orelli |
Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson. |
